- Aged 18-69, Spain, 2016
- Survey name
- Unnamed study
- N = 150
- Non Response
- 23,5% drop-outs
Assessment not reported, assumed internet and email.
- Authors's Label
- Appreciation of Beauty Intervention
- Our Classification
- Most items not reported
1: n = 43
0a: n = 52
0b: n = 55
- Related specification variables
- 1. TREATMENT GROUP
The 9 item Appreciation of Beauty and ExcelLence Scale (ABES; Martínez-Martí et al., 2016) measures the tendency to appreciate beauty, moral excellence, and nonmoral excellence (3 items for each subscale). A sample item to measure AB is "I am a person who is very sensitive to beauty." Rated from 1 (completely disagree) to 7 (completely agree).
Durung the 3-week program respondents had to do different exercises to keep participants engaged and to reach different goals.: video's, beauty journal, beauty awareness, beauty portfolio, environments, forum, past experiences and exposure to beauty.
0a. PLACEBO GROUP
The placebo condition focused on relationships with other people. Respondents had to choose 3 people (one person each week), with whom they had a different relationship in terms of closeness, from very close to not close at all. Then, participants answered the next questions every evening: (a) "What have I received from this person?", and (b) "What have I given to this person?"
This allowed the inclusion of daily exercises so it resembled the AB condition in this sense.
0b. WAITING LIST GROUP
Waitlist participants were informed that, because many people were interested in the study, they had been randomly assigned to do it in a second turn, but were requested, nonetheless, to complete the posttest and follow-up measures.
Observed Relation with Happiness
T0 T1 T2 T1-T0 T2-T0
Treatment 1.55 2.19 1.68 +0.64 +0.13
- Placebo 1.27 1.24 1.53 -0.13 +0.26
- Waiting list 1.25 1.36 1.45 +0.11 +0.20
- Placebo -1.6% +3.2%
- Waiting list +1.4% +2.5%
Treatment vs Placebo +9,6% -1,6%
Treatment vs Waiting List +6,6% -0,9%
Happiness measured at
T0 - pretest
T1 - directly after the 3-week experimeny
T2 - Follow-up 1 month after